Graeme Forrest, MBBS

CURRICULUM VITAE
Graeme Forrest, MBBS.
University of Maryland, Baltimore
Assistant Professor of Medicine

Date: 7/15/07

Personal Information
Business Address Division of Infectious Disease
Department of Medicine
University of Maryland School of Medicine
20 S. Penn St,Rm S403B
Baltimore, Maryland 21201
Phone Number (410) 706-5680
Fax Number (410) 706-8700
E-mail gforrest@medicine.umaryland.edu
Foreign Language Japanese (working knowledge)

Education
1989 M.B.B.S. University of Adelaide Medical School.
Frome Rd, Adelaide, SA, 5000, Australia.
Graduation April 1990.


Post Graduate Education and Training

1990 Internship (General) Royal Adelaide Hospital, Adelaide, South Australia
1991-1993 Junior Surgical Training Royal Adelaide Hospital, Adelaide, South Australia.
1993-1995 Post-Graduate Research Dept of Neurosurgery, Royal Adelaide Hospital, SA
1993-1995 Senior Emergency Room Registrar Royal Adelaide Hospital, Adelaide, South Australia.
.
1995 -1998 Internal Medicine Residency Columbus Hospital. (Affiliated with Northwestern University)
Chicago, Illinois.
1998 – 1999 Chief Medical Resident St Joseph’s Hospital (Affiliated with Northwestern University)
Catholic Health Partners, Chicago, Illinois.
1999-2001 Fellowship (Infectious Disease) University of Maryland, Baltimore, Maryland.

2001-2003 Instructor of Medicine University of Maryland, School of Medicine, Baltimore, MD.
2003- Assistant Professor of Medicine, non-tenure-track, University of Maryland, School of Medicine, Baltimore, MD.



Certifications
USMLE: Certificate No: 0512-113-2
Step 1 6/94 208
Step 2 3/94 229
Step 3 12/96 229
1998 Board Certified Internal Medicine : Certificate No 18394
2001 Board Certified Infectious Disease: Certificate No 18394

Medical Licensures
1997-2003 State of Illinois: Il-036-095787
2001- State of Maryland: D0057539


Professional Memberships
1999- Member, American College of Physicians
2002- Member, Infectious Disease Society of America
2002 - Member, HIV Medical Association
2001 - Member, American Society of Microbiology
2001 - Member, American Society of Transplantation
2003- Member, International Immunocompromised Hosts Society


Honors and Awards

Royal Adelaide Hospital Special Purposes Fund Small Grant 1993.
Royal Australasian College of Surgeons Foundation - Catherine Marie Enright Kelly Memorial Research Scholarship. 1994
Intern of the Year, Columbus Hospital 1995-96.
Second Prize in Bristol Myers Squibb Annual Scientific Research Meeting, 1996.
First Prize Bristol Myers Squibb Research Meeting 1997
Feinstein Award for Geriatrics, Catholic Health Partners 1998
American Society of Transplantation Training Grant 2001
Walter McCracken Scholarship, ICAAC 2001

Administrative Service
Institutional Service
Member, UMMS Antimicrobial Pharmacy and Therapeutics Sub-committee 2001- 2001-
Member, University of Maryland School of Medicine, Medical school Council 2002-2004 2002-2004
Residency Clinical Competence. Committee 2003-
Institutional Review Board Member 2007-
Director Antimicrobial Program University of Maryland 2001-
• Development of antimicrobial usage guidelines
• Optimize cost-effective practices
Assistant Director, Infectious Diseases Cancer Center Program 2004-
• Development and implementation of practice guidelines
• Optimal anti-infective use and cost containment
• Infection control
• Education

Local and National Service
National Service

Committee
2004-2005 Member Education Committee for American Transplantation Society
2002-2006 Bacterial & Mycosis Study Group, NIH.
2006- Bacterial & Mycosis Study Group, Education committee
2006- Editorial Board – Journal of Invasive Fungal Infections

Manuscript Review
2000- Clinical Infectious Diseases
2002- American Board of Internal Medicine
2003- American Journal of Transplantation
2005- Transplant Infectious Diseases
2005- Infection Control and Hospital Epidemiology
2007- Journal Antimicrobial Chemotherapy
2007- Journal of Infection

Abstract Reviewer
2006 American Transplantation Congress 2007 Abstract reviewer of Infectious Diseases section

Teaching Service
Basic Sciences
Preceptor, Small Group Sessions in Host Defenses in ID 2000-present
20 medical student, 2-4 clinical correlation classes/year
PD instructor for Sophomore medical students 2000-present
4 medical students annually for 12-16 sessions
Lecturer in Host Defenses Infectious Diseases, Medical school 2005-
1 lecture on Protein and Nucleic Acid Synthesis inhibitors
Clinical Sciences
Infectious Diseases Consult Attending, 6 months/year 2001-
1-2 fellows, 1 resident, 2 medical sudents
Baltimore Veteran’s Affairs Medical Teaching Attending, 1 month/year 2001-
3 residents, 3 students
Infectious Diseases Didactic Lectures 2001-
4 lectures per year
Internal Medicine Resident Lectures 2001-
4-6 lectures per year

Mentoring

Mentoring of Internal Medicine Residents
Alexander Kendziorsky 2001-2003
Kathleen Brennan 2003-2005
Kristina Mankes 2004-2006
Angela Kopack 2005-
Gina Zilioli 2005-

Mentoring of Medical Students
Internal Medicine Interest Group Director 2002-
6 lectures/year
Michael Sein 2006- Awarded IDSA summer scholarship



Clinical Research-Ongoing

1. Setnet – development of an online, integrated antimicrobial management program. NIH co-sponsor with Cereplex.
2. Invasive Mycoses: Evaluation of Non-Culture Based Diagnostic Techniques and Determination of Cytokine Profile Over the Course of Infection. NIH collaboration, Astellas,
3. DAP-REG-04-01 - CUBICINTM Outcomes Registry and Experience (CORE) for the Treatment of Serious Gram-positive Infections – Cubist Pharmaceuticals, inc.
4. A double-blind, randomized, controlled trial of rifaximin compared to vancomycin for the treatment of Clostridium difficile associated diarrhea. (CDAD). Salix.
5. Cancer Center outcomes registry database for detecting and treating invasive fungal infections. Pfizer,.
6. A phase iii, Double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by aspergillus species or other filamentous fungi. Basilea. WSA-CS4
7. A phase iii, Double blind, randomized study to evaluate the safety and efficacy of BAL8557 versus voriconazole in the treatment of candidemia and other invasive candida infection. Basilea. WSA-CS-008.
8. Mirabavir in preventing cytomegalovirus in patients who have undergone donor stem cell transplant or umbilical cord transplant. VP1263-300. Viropharma.


Cinical Research: Ended:

1. Emergency Compassionate Use Request: An open label non-comparitive protocol for the emergency use of voriconazole (UK109,496) in patients with life threatening invasive mycoses who are failing on currently available antifungal agents. FDA IND# (Oral) 48735 and (IV) #50410. Sponsor – Pfizer – not funded.
2. A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Safety and Efficacy of Interferon Gamma-1b (IFN- 1b) as an Adjunct to Voriconazole in the Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections Primary investigator. Sponsored by BAMSG and NIH. Primary Investigator. Not funded
3. A MultiCenter, Double-Blind, Comparative, Randomized Study to Evaluate the Efficiacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidaemia. Fujisawa.
4. A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus placebo for revention of Invasive Candidiasis and Candidemia in ICU patients. – Fujisawa
5. A phase III, multicenter, randomized, open-label, comparative study to assess the safety and efficacy of daptomycin compared to conventional therapy in the treatment of subjects with infective endocarditis and complicated bacteremia due to Staphylococcal aureus. Primary Investigator – Sponsor – Cubist-
6. A systematic collection of data regarding combination therapy with voriconazole plus caspofungin when used for the treatment of invasive aspergillosis in solid organ transplant recipients. 22 enrolled,
7. Evaluation of safety and feasibility of switching parenteral to oral anti-fungal therapy in neutropenic patients.
8. A Phase 3, randomized, double-blinded, comparative study of micafungin (FK463) versus caspofungin as antifungal treatment in patients with invasive candidiasis and candidemia. Astellas. 9 enrolled, $100,000.
9. Ntp / Mycograb / 003A Study: A Multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of Mycograb® as adjunctive therapy for cryptococcal meningitis in patients with AIDS. Neutec.
10. P02095 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections. Schering-Plough
11. Double-Blind, Randomized Controlled Trial of Voriconazole Plus Micafungin versus Voriconazole Plus Placebo in the Treatment of Patients with Proven or Probable Invasive Aspergillosis. Astellas.




Publications
Journal Articles (Peer Reviewed)
1. Forrest G.N., Jones, N.R., Scott, G. Acute presentation of meningioma due to hemorrhage following a motor vehicle accident. Jnl of Clinical Neuroscience. Vol 4, No 2 April 1997, Pg 266-268.
2. Simsir A., Forest G.., Oldach D., Henry M. Rhodococcus equi and cytomegalovirus pneumonia in a renal transplant patient: Diagnosis by fine needle aspiration biopsy.Diagnostic Cytopathology. Vol 24, No 2, 2001, Pg 129-131
3. Forrest G, Redfield RR. Photo Quiz: A 40 year old man with chronic elbow swelling after Minor trauma. Clin Infect. Dis. 2002, vol 34, Feb, pp354,398 & 399.
4. Forrest GN, Schimpff SC, Cross A. Editorial: Febrile neutropenia, colony stimulating factors and therapy:Time for a new methodology? Supportive Care Cancer. 2002;10:177-180
5. O’Shaughnessy E, Forrest G, Walsh TJ. Invasive aspergillus in patients with hematologic malignancies: recent advances and new challenges. Current Treatment Options in Infectious Diseases, vol 5 Issue 6, 2003. pp 507-516.
6. Forrest G. Gastrointestinal infections in immunocompromised hosts. Current Opinion in Gastroenterology. 2004,20:16-21.
7. Forrest G, Walsh TJ. Management of Invasive Fungal Infections in Patients with Hematological Malignancies: A Brief Review and Perspective. Support Cancer Therapy Vol 2, pp21-30. 2004. Editorial 31-33.
8. Forrest G: Nocardia Guidelines for American Society of Transplantation. American Journal of Transplantation. Vol 4, S10, pp47-50, 11/2004.
9. Chan-Tack KM, Forrest, G. A Man with headache and fevers. Clin Infect. Dis. Vol 39, p 1834, 2004.
10. Husain S, Munoz P, Forrest G, Alexander B, Somani J, Brennan K, Wagener M, Singh N. Infections Due to Scedosporium apiospermun and prolificans in Transplant Recipients: Clinical Characteristics and Impact of Antifungal Agent Therapy on Outcome. Clin Infect Disease, 2005: 40, pp 89-99..
11. Chow S, Forrest G. A Liver Transplant Recipient with an Infected Explanted Liver. Clin Infect Disease, 2005:40; 279 & 313.
12. Forrest GN, Mackowiak PA, Schlossberg MC, Myer CF. A 76 year-old man with fever and weakness. Am J. Med Sci. 2005:330;32-35.
13. Mehta S, Johnson J, Venezia R, Forrest G. Emergence of linezolid-resistant Enterococcus faecalis in a neutropenic patient. J Hosp Infect. 2006:62;125-127.
14. Rizk M, Johnson J, Forrest G, Mankes K, Meiller T, Venezia R. Candida dubiliniensis fungemia. Clin Infect Dis 2005:41;1064-67.
15. Chan-Tack KM, Forrest G. Failure of Interferon alpha-2b in a patient with West Nile Virus Meningoencephalitis and Acute Flaccid Paralysis. Scand Jnl of Infect Dis. 2005:11-12;944-946.
16. Dinits-Pensky M, Forrest GN, Cross AS, Hise MK. The Use of Vaccines in Adult Patients with Renal Disease. Am. J Kidney Dis. 2005:46;997-1011.
17. Thom K, Forrest G. Gastrointestinal infections in immunocompromised hosts. Current Opin. Gastroenterol. 2006:22;18-23.
18. Chan-Tack K, Forrest G. West Nile Virus Meningoencephalitis and Acute Flaccid Paralysis after
Infliximab Treatment. J Rheumatol. 2006:33;191-192.
19. Singh N, Limaye A, Forrest GN et al. Combination of Voriconazole and Caspofungin as Primary Therapy for Invasive Aspergillosis in Solid Organ Transplant Recipients: Prospective, Multicenter Observational Study. Transplantation 2006:81;320-326.
20. Forrest GN, Mehta S, Weekes E, Lincalis D, Johnson JK, Venezia R. The Financial Impact of a rapid in-situ Hybridization Assay with an Antimicrobial Management Program for Coagulase Negative Staphylococci Blood Cultures at a University Teaching Hospital. Jnl Antimicrob Chemotherapy. 2006;58:154-58.
21. McGregor J, Weekes E, Forrest GN, Standiford HA, Perencevich E, Furuno J, Harris A. Hospital Antibiotic Stewardship Improved By Computerized Clinical Decision Support System: A Patient-Randomized Controlled Trial. Jnl of the American Medical Informatics Association. 2006;13:378-384.
22. Singh N, Limaye A, Forrest GN et al. Late-Onset Invasive Aspergillosis in Organ Transplant Recipients in the Current Era. Medical Mycology. 2006;44:444-449.
23. Fowler V, Boucher H, Corey R, Abrutyn E, Karchmer AW, Rupp M, Levine D, Chambers H, Tally F, Cabell C, Link A, DeMeyer , Filler S, Zervos M, Cook P, Parsonnet J, Bernstein J, Price C, Forrest GN, et al. Daptomycin compared to conventional therapy in the treatment of subjects with infective endocarditis and complicated bacteremia due to Staphylococcal aureus. New England Jnl Med. 2006;355:653-665.
24. Henn S. Forrest GN. Febrile neutropenia associated with painful lesions of the palms and digits. Clin Infect. Dis. 2006;43:747.
25. Forrest GN, Mankes K, Jabra-Rizk MA, Weekes E, Johnson JK, Lincalis DP, Venezia RA. Impact of PNA FISH of Candida albicans on antifungal therapy, mortality and costs. J Clin Micro. 2006;44;3381-3383.
26. Anaissie EH, Segal BJ, Graybill JR et al. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin. Infect Dis. 2006;43:1031-39.
27. Forrest GN. Role of Antifungal Susceptibility Testing in Patient Management. Current Opinion In Infectious Diseases. 2006;19;538-543.
28. Forrest GN, Rasetto F, Akpek G, Philosophe B. Safety and Efficacy of Micafungin in Transplantation Recipients. Transplantation. 2006:82;1549
29. Arnold TM, Forrest GN, Messmer KJ. Polymyxin antibiotics for Gram-negative infections. Am. J. Health System Pharm. 2007;64;819-26.
30. Polk C, Forrest G, Cross A. Cellulitis in a patient with leukemia. Clin Infect Dis. 2007;44;1220-1,1249-50.
31. Forrest GN. PNA FISH: present and future impact on patient management. Expert Rev Mol Diagn. 2007 May;7:231-6.
32. Forrest GN, Mankes K. Outcomes of invasive zygomycosis infections in renal transplant recipients. Transpl Infect Dis. 2007 Jun;9:161-4.

In Press
1. Riedel DJ, Johnson JK, Forrest GN. Rhodotorula glutinis fungemia in a liver-kidney transplant. Transplant Infectious Diseases. . E-pub 17605726
2. Ilyas C, Forrest G, Akpek G. Potential clinical benefit of donor lymphocyte infusion in the treatment of refractory invasive fungal pneumonia. Bone Marrow Transplantation. E-pub 17618316.

Chapters:
Forrest, GN, Oldach D. Chapter 27, Chloramphenicol. Gorbach’s Textbook of Infectious Disease. Lippincott Williams and Wilkins, 2003
Forrest, GN, Oldach, D. Chapter 22 Macrolides and Clindamycin. . Gorbach’s Textbook of Infectious Disease. Lippincott Williams and Wilkins, 2003.


Journal Articles (Not-Peer Reviewed)

1. Forrest G: Scedosporium soft-tissue infections. MD Consult Infectious Disease. April 29, 2002. http://www.mdconsult.com.

Abstracts

1) Forrest G, Joshi M, Bocchichio G, Brull R, Caplan E, Scalea T. Invasive Group A Streptococcal Infections: Impact of initial antibiotic selection on the length of stay. ICAAC 2001-A-37672.
2) Forrest G, Joshi M, Bocchichio G, Brull R, Caplan E, Scalea T. Mortality related to initial antibiotic selection in Perineal necrotizing fasciitis (PNF). ICAAC 2001-A-37865.
3) Forrest G, Chan S, Donnenberg M, Standiford H. Development and Implementation of an antimicrobial management team with significant cost savings at a university hospital. ICAAC 2002-A-2520.
4) Chan S, Forrest G, Kleinberg M, Standiford H, Donnenberg M. Significant cost savings with implementation of lipid amphotericin B guidelines in a university cancer center. ICAAC 2002-A-2539.
5) Kendziorski A, Mansoor A, Chan S, Forrest G. Empiric fluconazole use is associated with the development of invasive non-Candida albicans infections in Intensive care units. ICAAC 2002-A-3343.
6) Forrest G, Chan S, Kleinberg M. Outcomes of Caspofungin Therapy and the Neutropenic Host in a University Cancer Center. IDSA 2002-100841.
7) Couch KA, Chan S, Cincotta E, Piper JA, Forrest GN. Comparative Nephrotoxicity, Adverse Events, and Clinical Outcomes with Lipid-Associated Amphotericin B Products. Focus on Fungal Infections, Poster #47, Hawaii, 2003.
8) Lewandowski L, Forrest G. Successful treatment of Scediosporium apiospermium septic arthritis in a neutropenic patient. Maryland Chapter American College of Physicians, 5/03.
9) DeMore J, Forrest G. Libman Sacks endocardititis. Maryland Chapter American College of Physicians, 5/03.
10) Forrest G, Chan S, Donnenberg M, Standiford H. The Cost Benefit After Implementation of an Automatic IV-to-PO Conversion Policy on Target Antimicrobials. IDSA-, 2003, #160.*
11) Direnzo-Berkowicz T, Chan S, Forrest G. The Use of Valganciclovir (Valcyte®) for Cytomegalovirus (CMV)Prophylaxis in Solid Organ Transplantation. IDSA-2003, #365.
12) Forrest G, Adams K, Mayoryk S, Hebden J, Standiford H, Johnson S. Early Enteral Feeding and Targeted Oral Fluconazole to Reduce Candidemia in the Surgical Intensive Unit. IDSA-2004, #237.
13) Forrest G, Weekes E, Standiford H. Antimicrobial Management Program: Continual Cost Savings at a Large Teaching Medical Center. IDSA-2004, #328.
14) Brennan K, Malat G, Wiland A, Forrest G. An Association Between Ground Construction and Invasive Aspergillosis in Renal Transplant Recipients. IDSA-2004, #674.
15) Arnold T, Donegan S, Kleinberg M, Forrest G. Cost-Effectiveness of Implementing an IV Antifungal to Oral Voriconazole Conversion in a Cancer Center. IDSA-2004, #690.
16) Singh N, Munoz P, Forrest G, Alexander B, Brennan K, Somani J, Husain S. Scedosporium Infections in Organ Transplant Recipients: Impact of Antifungal Agent Therapy on Outcome. ICAAC-2004, #1316.
17) McGregor J, Weekes E, Forrest G.N, Standiford H.C, Wright MO, Peterson DE, Harris AD. Hospital Antibiotic Stewardship Improved By An Automated Infection Surveillance Management Tool: A Randomized Control Study. SHAE-2005.
18) Forrest G, Mankes K. Outcomes of hugh dose lipid amphotericin B therapy in the treatment of invasive zygomycosis infections. Focus on Fungals, #21, Miami, 2005.
19) Rizk M, Johnson J, Forrest GN, Mankes K, Meiller T, Venezia R. Candida dubiliniensis fungemia. ASM general meeting 6/2005
20) Thom K, Mankes K, Forrest GN, Rizk MA, Caplan M, Johnson J, Venezia RA. A treatment algorithm using rapid diagnosis of candidemia with fluconazole susceptibility testing. ICAAC-2005, #2381.
21) Singh N, Limaye A, Safdar N, Forrest GN, Pursell K, Munoz P, Russo F, Montoya J, Aguado J, Patton P, Houston S, Del Busto R, Husain S. Safety and tolerability of voriconazole plus caspofungin in solid organ transplant recipients with invasive aspergillosis. ICAAC-2005, #584
22) Singh N, Limaye A, Safdar N, Forrest GN, Pursell K, Munoz P, Russo F, Montoya J, Aguado J, Patton P, Houston S, Del Busto R, Husain S. Late onset invasive aspergillosis in solid organ transplant recipientsin the current era. ICAAC-2005, #585
23) Singh N, Limaye A, Safdar N, Forrest GN, Pursell K, Munoz P, Russo F, Montoya J, Aguado J, Patton P, Houston S, Del Busto R, Kontoyiannis D, Husain S. Combination of voriconazole and caspofungin as primary therapy of invasive aspergillosis in solid organ transplant recipients. ICAAC-2005, #587, Oral presentation.
24) Mankes K, Forrest GN, Jabra-Rizk MA, Johnson JK, Venezia RA. Outcomes of Peptide Nucleic Acid Fluorescence in situ Hybridization Probes for Rapid Identification of Candida albicans. IDSA-2005, #276
25) McGregor J, Perencevich EN, Weekes E, Forrest GN, Peterson DE, Harris AD. Hospital Antibiotic Stewardship Improved by an Automated Infection Surveillance Management Tool: a Randomized Control study. IDSA-2005,#414, poster.
26) Doshi S, Weekes E, Forrest GN. Comparison of Two Intervention Methods on the Prescribing of Piperacillin/tazobactam. IDSA-2005, #540.
27) Pajoumand M, Forrest GN, Wright MO, Shanholtz C. Retrospective Review of Outcomes of Bloodstream Infections in the Medical Intensive Care unit. IDSA-2005, #605.
28) McGregor J, Perencevich EN, Weekes E, Forrest GN, Peterson DE, Harris AD. Hospital Antibiotic Stewardship Improved by an Automated Infection Surveillance Management Tool: a Randomized Control study. IDSA-2005, #686. Oral.
29) Forrest GN, Weekes E, Holck P, Harris AD, Peterson DE. Automated Detection of Ineffective Antibiotic Coverage of Resistant Gram Negative Bloodstream infections. IDSA-2005, #1166.*
30) Forrest GN, Akpek G, Donovan B, Lamp K. Daptomycin use in patients with hematological cancer history: Post-marketing experience in a registry. American Society of Hematology Meeting, 2005, Atlanta #3132.
31) Forrest GN, Weekes E. The safety and cost-effectiveness of using micafungin at a tertiary care hospital. Focus on Fungal Infections, 2006, Las Vegas #77.
32) Johnson JK, Roberts AA, Forrest GN, Lincalis DP, Venezia RA. Rapid Identification of Enterococcus species in Positive Blood Cultures with Therapeutic Implications. ASM-#C-147, Orlando 2006.
33) Forrest GN, Rasetto F, Akpek G, Philosophe B. Clinical safety and efficacy of micafungin in transplant recipients. World Transplant Congress, Boston 2006.
34) Forrest GN, Donovan B, Lamp K. Daptomycin (DAP) Use in Patients (pts) with Septic Arthritis (SA): Post-Marketing Experience from CORE 2005. ICAAC, San Francisco 2006. L-1556.
35) Forrest GN, Weekes E, Jabra-Rizk MA, Lincalis D, Johnson JK, Venezia RA. Effectiveness of a Treatment Algorithm for Candidemia Using Rapid Diagnosis. ICAAC, San Francisco 2006. M-1601.
36) Henn S, Forrest GN. Methicillin Resistant Staphylococcus Aureus Bacteremia Treated with Linezolid: A Retrospective Review of Outcomes. ICAAC, San Francisco 2006. K-0788.
37) Uche, A, Forrest GN. Frequency of Active Infective Endocarditis by Mode of Echocardiography in HIV-Infected Patients with Staphylococcus Aureus Bacteremia. ICAAC, San Francisco 2006. K-805.
38) Uche A, Forrest GN. Outcomes of MRSA Bacteremia in HIV Infected Patients. ICAAC, San Francisco 2006. K-0779.
39) Kopack A, Forrest GN. Effects of HMGcoA Reductase Inhibitors (Statins) on Patients with Candidemia. San Francisco 2006. M-908.
40) Toombs L, Weekes E, Forrest G, Lincalis D, Johnson JK, Venezia RA. Impact of Peptide Nucleic Acid (PNA) Fluorescence in situ Hybridization (FISH) for Enterococcal blood stream infections. IDSA, Toronto, 2006. Oral Presentation 131.
41) Lane S, Forrest GN, Venezia RA, Johnson JK. Increasing Resistance to Vancomycin and Daptomycin in MRSA Isolates. IDSA, Toronto, 2006. #244.
42) Boucher HW, Corey GR, Forrest G, Zervos M, Campion M, Fowler V. Length of Therapy and Outcome in S. aureus bacteremia and Endocarditis (SAB/SAIE): < 14 Days of Therapy Associated with Lower Success Rates in Uncomplicated SAB (uB). IDSA, Toronto, 2006. #367
43) Yeung SY, Weekes E, Forrest GN, Johnson JK, Venezia RA. Clinical Efficacy of Using Vancomycin MICs for Treating Methicillin Resistant Staphylococcus aureus Bacteremia. IDSA, Toronto, 2006. #370.
44) Uche A, Forrest G. Staphylococcus aureus Bacteremia In HIV-infected patients In The HAART Era. IDSA, Toronto, 2006. #370.
45) Chizmar T, Chim J, Forrest GN, Gammie JS. Surgical Outcomes from Mitral Valve Infective Endocarditis. IDSA, Toronto, 2006. #435.
46) Patel D, Forrest G. Treatment Outcomes of Candida Endocarditis. IDSA, Toronto, 2006. #551.
47) Forrest G, Donovan B, Lamp K, Freidrich L. Daptomycin (DAP) Use in Patients (pts) with Septic Arthritis (SA): Post-Marketing Experience from CORE 2005. American College of Clinical Pharmacists Meeting, St Louis, 2006. #140E.
48) Toombs L, Weekes E, Forrest G, Lincalis D, Johnson JK, Venezia RA. Impact of Peptide Nucleic Acid (PNA) Fluorescence in situ Hybridization (FISH) for Enterococcal blood stream infections. 14th annual First Coast Symposium, Jacksonville, Fl. 2007. Poster #3.
49) Forrest G, Weekes E, Johnson JK. Association of Candida parapsilosis candidemia and usage of new antifungals. Focus on Fungal Infections 15, San Diego, Ca. #62.

Major Invited Speeches:

Local:
2002: Baltimore Veterans Affairs Medical Center, Clinicopathological Conference. Baltimore, MD.
2002 6th Annual Johns Hopkins Fellow Course. Baltimore, MD. (Invited Speaker)
2002 Department of Medicine Grand Rounds, Maryland General Hospital. Baltimore, MD.
(Invited Speaker)
2002 Department of Medicine Grand Rounds, University of Maryland. Baltimore, MD.
(Invited Speaker)
2003 Department of Medicine Grand Rounds, Maryland General Hospital. Baltimore, MD.
(Invited Speaker)
2003 Department of Medicine Grand Rounds, Washington Hospital Center, Washington, DC.
(Invited Speaker)
2004 Department of Medicine Grand Rounds, Mercy Medical Center, Baltimore, MD.
(Invited Speaker)
2005 Midatlantic Regional Conference for Nurse Practitioners. College Park, MD.
(Invited Speaker)
2006 Midatlantic Regional Conference for Nurse Practitioners. College Park, MD.
(Invited Speaker)
2007 Department of Medicine Grand Rounds, University of Maryland. Baltimore, MD.
(Invited Speaker)





National:
1997 American College of Physicians Annual Clinical Vignette Meeting of Illinois branch.
Chicago, Illinois. (Oral Presentation)
2002 Department of Medicine Grand Rounds, Sioux City, Iowa. (Invited Speaker)
2005 Department of Medicine Grand Rounds, Charleston Medical Center, WV.
(Invited Speaker)
2005 Impact of Rapid Diagnostics on Antimicrobial management. IDSA, San Francisco, Ca.
(Invited Speaker)
2005 Impact of Rapid Diagnostics on Antimicrobial management. ICAAC, Washington, DC.
(Invited Speaker)
2006 Role of MIC in determining appropriate therapeutic approaches and potential drug interactions.
Honolulu, Hi. (Invited Speaker) Symposia. Tandem BMT meeting.
2007 Meet The Expert. Rapid Diagnostics. 16th annual Society of Hospital Epidemiology of America Meeting, Baltimore, MD, April 15th.
2007 Meet The Expert. Antimicrobial management programs. 16th annual Society of Hospital Epidemiology of America Meeting, Baltimore, MD, April 16th

International:
1995 Royal Australian College of Surgeons Annual Scientific Meeting, Perth, Western Australia.
(Oral presentation)